View More View Less
  • 1 Infectious and Tropical Diseases Research Center, Health Research Institute, Ahvaz Jundishapur University of Medical Sciences, Ahvaz, Iran
  • | 2 Department of Microbiology, School of Medicine, Ahvaz Jundishapur University of Medical Sciences, Ahvaz, Iran
  • | 3 Iranian Study Group on Microbial Drug Resistance, Iran
  • | 4 Department of Basic Sciences, Division of Biochemistry and Molecular Biology, Faculty of Veterinary Medicine, Shahid Chamran University of Ahvaz, Ahvaz, Iran
  • | 5 Tropical Medicine Ward, Razi Teaching Hospital, Ahvaz Jundishapur University of Medical Sciences, Ahvaz, Iran
Restricted access

Purchase article

USD  $25.00

1 year subscription (Individual Only)

USD  $784.00

Abstract

The management of multidrug-resistant (MDR) and extensively drug-resistant tuberculosis (XDR-TB) presents a main challenge and the drug options for treating these infections are very limited. Linezolid (LNZ) has recently been approved for the treatment of MDR and XDR-TB. But, there are narrow data on genotypic and phenotypic LNZ resistance in clinical isolates. So, we aimed to determine the prevalence of LNZ resistance and to identify the mutations associated with LNZ resistance among clinical MDR-TB isolates. The minimum inhibitory concentration (MIC) values of LNZ for 22 MDR-TB isolates were determined by broth microdilution method. All MDR-TB isolates were sequenced in the rrl and rplC genes conferring LNZ resistance. LNZ resistance was found in 3 (13.6%) of 22 MDR-TB isolates. The MICs of LNZ were 8 μg/mL for two isolates and 16 μg/mL for one isolate. The 421 (A/G) and 449 (T/A) mutations in rplC gene were detected in one of the LNZ-resistant isolates. There was no mutation in rrl gene. The results reveal that the prevalence of LNZ-resistant isolates is 13.6% among MDR-TB isolates and drug susceptibility testing (DST) against LNZ is useful in the management of complicated and drug-resistant cases. However, further studies could identify other possible genetic mechanism of resistance in TB.

  • 1.

    Wasserman S , Louw G , Ramangoaela L , Barber G , Hayes C , Omar SV , et al.. Linezolid resistance in patients with drug-resistant TB and treatment failure in South Africa. J Antimicrob Chemother 2019; 74: 237784. https://pubmed.ncbi.nlm.nih.gov/31081017/.

    • Crossref
    • Search Google Scholar
    • Export Citation
  • 2.

    WHO. Global tuberculosis report 2019. License: CC BY-NCSA 3.0 IGO. Geneva: World Health Organization; 2019.

  • 3.

    Yang JS , Kim KJ , Choi H , Lee SH . Delamanid, bedaquiline, and linezolid minimum inhibitory concentration distributions and resistance-related gene mutations in multidrug-resistant and extensively drug-resistant tuberculosis in Korea. Ann Lab Med 2018; 38: 5638. https://pubmed.ncbi.nlm.nih.gov/30027700/.

    • Crossref
    • Search Google Scholar
    • Export Citation
  • 4.

    Sotgiu G , Centis R , D'Ambrosio L , Alffenaar J-WC , Anger HA , Caminero JA , et al.. Efficacy, safety and tolerability of linezolid containing regimens in treating MDR-TB and XDR-TB: systematic review and meta-analysis. Eur Respir J 2012; 40: 143042. https://pubmed.ncbi.nlm.nih.gov/22496332/.

    • Crossref
    • Search Google Scholar
    • Export Citation
  • 5.

    Singh B , Cocker D , Ryan H , Sloan DJ . Linezolid for drug‐resistant pulmonary tuberculosis. Cochrane Database Syst Rev CD012836; 2019. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6426281/.

    • Crossref
    • Search Google Scholar
    • Export Citation
  • 6.

    Organization WHO. WHO consolidated guidelines on tuberculosis: module 4: treatment: drug-resistant tuberculosis treatment; 2020.

  • 7.

    Agyeman AA , Ofori-Asenso R . Efficacy and safety profile of linezolid in the treatment of multidrug-resistant (MDR) and extensively drug-resistant (XDR) tuberculosis: a systematic review and meta-analysis. Ann Clin Microbiol Antimicrob 2016; 15: 117. https://pubmed.ncbi.nlm.nih.gov/27334498/.

    • Crossref
    • Search Google Scholar
    • Export Citation
  • 8.

    Fortún J , Martín-Dávila P , Navas E , Pérez-Elías MJ , Cobo J , Tato M , et al.. Linezolid for the treatment of multidrug-resistant tuberculosis. J Antimicrob Chemother 2005; 56: 1805. https://pubmed.ncbi.nlm.nih.gov/15911549/.

    • Crossref
    • Search Google Scholar
    • Export Citation
  • 9.

    Tornheim JA , Intini E , Gupta A , Udwadia ZF . Clinical features associated with linezolid resistance among multidrug resistant tuberculosis patients at a tertiary care hospital in Mumbai, India. J Clin Tuberc Other Mycobact Dis 2020; 20: 100175. https://pubmed.ncbi.nlm.nih.gov/32775702/.

    • Crossref
    • Search Google Scholar
    • Export Citation
  • 10.

    Beckert P , Hillemann D , Kohl TA , Kalinowski J , Richter E , Niemann S , et al.. rplC T460C identified as a dominant mutation in linezolid -resistant Mycobacterium tuberculosis strains. Antimicrob Agents Chemother 2012; 56: 27435. https://aac.asm.org/content/56/5/2743.

    • Crossref
    • Search Google Scholar
    • Export Citation
  • 11.

    Kazemian H , Haeili M , Kardan YJ , Rezaei F , Gizaw FS , Zahednamazi F , et al.. Antimycobacterial activity of linezolid against multidrug-resistant and extensively drug-resistant strains of Mycobacterium tuberculosis in Iran. Int J Antimicrob Agents 2015; 45: 668. https://pubmed.ncbi.nlm.nih.gov/25795315/.

    • Crossref
    • Search Google Scholar
    • Export Citation
  • 12.

    Singla R , Caminero JA , Jaiswal A , Singla N , Gupta S , Bali RK , et al.. Linezolid: an effective, safe and cheap drug for patients failing multidrug-resistant tuberculosis treatment in India. Eur Respir J 2012; 39: 95662. https://erj.ersjournals.com/content/39/4/956.

    • Crossref
    • Search Google Scholar
    • Export Citation
  • 13.

    Ahmed I , Jabeen K , Inayat R , Hasan R . Susceptibility testing of extensively drug-resistant and pre-extensively drug-resistant Mycobacterium tuberculosis against levofloxacin, linezolid, and amoxicillin-clavulanate. Antimicrob Agents Chemother 2013; 57: 25225. https://pubmed.ncbi.nlm.nih.gov/23507286/.

    • Crossref
    • Search Google Scholar
    • Export Citation
  • 14.

    Hu M , Fu L , Wang B , Xu J , Guo S , Zhao J , et al.. Genetic and virulence characteristics of linezolid and pretomanid dual drug-resistant strains induced from Mycobacterium tuberculosis in vitro. Infect Drug Resist 2020; 13: 1751. https://pubmed.ncbi.nlm.nih.gov/32606825/.

    • Crossref
    • Search Google Scholar
    • Export Citation
  • 15.

    World Health Organization. 2018. Policy quidance on drug-susceptibility (DST) of second line antituberculosis drugs. WHO/HTM/TB/2018.392 World Health Organization G, Switzerland.

    • Search Google Scholar
    • Export Citation
  • 16.

    NCBI/Primer-BLAST: Finding primers specific to your PCR template (using Primer3 and BLAST). Available from: www.ncbi.nlm.nih.gov/tools/primer-blast/.

    • Search Google Scholar
    • Export Citation
  • 17.

    Zhang Z , Pang Y , Wang Y , Liu C , Zhao Y . Beijing genotype of Mycobacterium tuberculosis is significantly associated with linezolid resistance in multidrug-resistant and extensively drug-resistant tuberculosis in China. Int J Antimicrob Agents 2014; 43: 2315. https://pubmed.ncbi.nlm.nih.gov/24439458/.

    • Crossref
    • Search Google Scholar
    • Export Citation
  • 18.

    Hillemann D , Rüsch-Gerdes S , Richter E . In vitro-selected linezolid-resistant Mycobacterium tuberculosis mutants. Antimicrob Agents Chemother 2008; 52: 8001. https://pubmed.ncbi.nlm.nih.gov/18070973/.

    • Crossref
    • Search Google Scholar
    • Export Citation
  • 19.

    Zhang S , Chen J , Cui P , Shi W , Shi X , Niu H , et al.. Mycobacterium tuberculosis mutations associated with reduced susceptibility to linezolid. Antimicrob Agents Chemother 2016: 294115. https://pubmed.ncbi.nlm.nih.gov/26810645/.

    • Search Google Scholar
    • Export Citation
  • 20.

    Klitgaard RN , Ntokou E , Nørgaard K , Biltoft D , Hansen LH , Trædholm NM , et al.. Mutations in the bacterial ribosomal protein l3 and their association with antibiotic resistance. Antimicrob Agents Chemother 2015; 59: 351828. https://pubmed.ncbi.nlm.nih.gov/25845869/.

    • Crossref
    • Search Google Scholar
    • Export Citation
  • 21.

    Richter E , Rüsch-Gerdes S , Hillemann D . First linezolid-resistant clinical isolates of Mycobacterium tuberculosis. Antimicrob Agents Chemother 2007; 51: 15346. https://pubmed.ncbi.nlm.nih.gov/17242139/.

    • Crossref
    • Search Google Scholar
    • Export Citation
  • 22.

    Escribano I , Rodriguez J , Llorca B , Garcia-Pachon E , Ruiz M , Royo G . Importance of the efflux pump systems in the resistance of Mycobacterium tuberculosis to fluoroquinolones and linezolid. Chemotherapy 2007; 53: 397401. https://pubmed.ncbi.nlm.nih.gov/17934259/.

    • Crossref
    • Search Google Scholar
    • Export Citation
  • 23.

    Sander P , Belova L , Kidan Y , Pfister P , Mankin A , Böttger E . Ribosomal and non‐ribosomal resistance to oxazolidinones: species‐specific idiosyncrasy of ribosomal alterations. Mol Microbiol 2002; 46: 1295304. https://pubmed.ncbi.nlm.nih.gov/12453216/.

    • Crossref
    • Search Google Scholar
    • Export Citation
  • 24.

    Almeida Da Silva PE , Palomino JC . Molecular basis and mechanisms of drug resistance in Mycobacterium tuberculosis: classical and new drugs. J Antimicrob Chemother 2011; 66: 141730. https://pubmed.ncbi.nlm.nih.gov/21558086/.

    • Crossref
    • Search Google Scholar
    • Export Citation

 

The author instruction is available in PDF.
Please, download the file from HERE

Senior editors

Editor-in-Chief: Prof. Dóra Szabó (Institute of Medical Microbiology, Semmelweis University, Budapest, Hungary)

Managing Editor: Dr. Béla Kocsis (Institute of Medical Microbiology, Semmelweis University, Budapest, Hungary)

Co-editor: Dr. Andrea Horváth (Institute of Medical Microbiology, Semmelweis University, Budapest, Hungary)

Editorial Board

  • Prof. Éva ÁDÁM (Institute of Medical Microbiology, Semmelweis University, Budapest, Hungary)
  • Prof. Sebastian AMYES (Department of Medical Microbiology, University of Edinburgh, Edinburgh, UK.)
  • Dr. Katalin BURIÁN (Institute of Clinical Microbiology University of Szeged, Szeged, Hungary; Department of Medical Microbiology and Immunobiology, University of Szeged, Szeged, Hungary.)
  • Dr. Orsolya DOBAY (Institute of Medical Microbiology, Semmelweis University, Budapest, Hungary)
  • Prof. Ildikó Rita DUNAY (Institute of Inflammation and Neurodegeneration, Medical Faculty, Otto-von-Guericke University, Magdeburg, Germany; Center for Behavioral Brain Sciences (CBBS), Magdeburg, Germany)
  • Prof. Levente EMŐDY(Department of Medical Microbiology and Immunology, University of Pécs, Pécs, Hungary.)
  • Prof. Anna ERDEI (Department of Immunology, Eötvös Loránd University, Budapest, Hungary, MTA-ELTE Immunology Research Group, Eötvös Loránd University, Budapest, Hungary.)
  • Prof. Éva Mária FENYŐ (Division of Medical Microbiology, University of Lund, Lund, Sweden)
  • Prof. László FODOR (Department of Microbiology and Infectious Diseases, University of Veterinary Medicine, Budapest, Hungary)
  • Prof. József KÓNYA (Department of Medical Microbiology, University of Debrecen, Debrecen, Hungary)
  • Prof. Yvette MÁNDI (Department of Medical Microbiology and Immunobiology, University of Szeged, Szeged, Hungary)
  • Prof. Károly MÁRIALIGETI (Department of Microbiology, Eötvös Loránd University, Budapest, Hungary)
  • Prof. János MINÁROVITS (Department of Oral Biology and Experimental Dental Research, University of Szeged, Szeged, Hungary)
  • Prof. Béla NAGY (Centre for Agricultural Research, Institute for Veterinary Medical Research, Budapest, Hungary.)
  • Prof. István NÁSZ (Institute of Medical Microbiology, Semmelweis University, Budapest, Hungary)
  • Prof. Kristóf NÉKÁM (Hospital of the Hospitaller Brothers in Buda, Budapest, Hungary.)
  • Dr. Eszter OSTORHÁZI (Institute of Medical Microbiology, Semmelweis University, Budapest, Hungary)
  • Prof. Rozália PUSZTAI (Department of Medical Microbiology and Immunobiology, University of Szeged, Szeged, Hungary)
  • Prof. Peter L. RÁDY (Department of Dermatology, University of Texas, Houston, Texas, USA)
  • Prof. Éva RAJNAVÖLGYI (Department of Immunology, Faculty of Medicine, University of Debrecen, Debrecen, Hungary)
  • Prof. Ferenc ROZGONYI (Institute of Laboratory Medicine, Semmelweis University, Budapest, Hungary)
  • Prof. Zsuzsanna SCHAFF (2nd Department of Pathology, Semmelweis University, Budapest, Hungary)
  • Prof. Joseph G. SINKOVICS (The Cancer Institute, St. Joseph’s Hospital, Tampa, Florida, USA)
  • Prof. Júlia SZEKERES (Department of Medical Biology, University of Pécs, Pécs, Hungary.)
  • Prof. Mária TAKÁCS (National Reference Laboratory for Viral Zoonoses, National Public Health Center, Budapest, Hungary.)
  • Prof. Edit URBÁN (Department of Medical Microbiology and Immunology University of Pécs, Pécs, Hungary; Institute of Translational Medicine, University of Pécs, Pécs, Hungary.)

 

Editorial Office:
Akadémiai Kiadó Zrt.
Budafoki út 187-187, A/3, H-1117 Budapest, Hungary

Editorial Correspondence:
Acta Microbiologica et Immunologica Hungarica
Institute of Medical Microbiology
Semmelweis University
P.O. Box 370
H-1445 Budapest, Hungary
Phone: + 36 1 459 1500 ext. 56101
Fax: (36 1) 210 2959
E-mail: amih@med.semmelweis-univ.hu

 Indexing and Abstracting Services:

  • Biological Abstracts
  • BIOSIS Previews
  • CAB Abstracts
  • Chemical Abstracts
  • Global Health
  • Index Medicus
  • Index Veterinarius
  • Medline
  • Referativnyi Zhurnal
  • SCOPUS
  • Science Citation Index Expanded
2020  
Total Cites 662
WoS
Journal
Impact Factor
2,048
Rank by Immunology 145/162(Q4)
Impact Factor Microbiology 118/137 (Q4)
Impact Factor 1,904
without
Journal Self Cites
5 Year 0,671
Impact Factor
Journal  0,38
Citation Indicator  
Rank by Journal  Immunology 146/174 (Q4)
Citation Indicator  Microbiology 120/142 (Q4)
Citable 42
Items
Total 40
Articles
Total 2
Reviews
Scimago 28
H-index
Scimago 0,439
Journal Rank
Scimago Immunology and Microbiology (miscellaneous) Q4
Quartile Score Medicine (miscellaneous) Q3
Scopus 438/167=2,6
Scite Score  
Scopus General Immunology and Microbiology 31/45 (Q3)
Scite Score Rank  
Scopus 0,760
SNIP
Days from  225
sumbission
to acceptance
Days from  118
acceptance
to publication
Acceptance 19%
Rate

2019  
Total Cites
WoS
485
Impact Factor 1,086
Impact Factor
without
Journal Self Cites
0,864
5 Year
Impact Factor
1,233
Immediacy
Index
0,286
Citable
Items
42
Total
Articles
40
Total
Reviews
2
Cited
Half-Life
5,8
Citing
Half-Life
7,7
Eigenfactor
Score
0,00059
Article Influence
Score
0,246
% Articles
in
Citable Items
95,24
Normalized
Eigenfactor
0,07317
Average
IF
Percentile
7,690
Scimago
H-index
27
Scimago
Journal Rank
0,352
Scopus
Scite Score
320/161=2
Scopus
Scite Score Rank
General Immunology and Microbiology 35/45 (Q4)
Scopus
SNIP
0,492
Acceptance
Rate
16%

 

Acta Microbiologica et Immunologica Hungarica
Publication Model Online only Hybrid
Submission Fee none
Article Processing Charge 1100 EUR/article
Regional discounts on country of the funding agency World Bank Lower-middle-income economies: 50%
World Bank Low-income economies: 100%
Further Discounts Editorial Board / Advisory Board members: 50%
Corresponding authors, affiliated to an EISZ member institution subscribing to the journal package of Akadémiai Kiadó: 100%
Subscription fee 2021 Online subsscription: 652 EUR / 812 USD
Subscription fee 2022 Online subsscription: 662 EUR / 832 USD
Print + online subscription: 740 EUR / 930 USD
Subscription Information Online subscribers are entitled access to all back issues published by Akadémiai Kiadó for each title for the duration of the subscription, as well as Online First content for the subscribed content.
Purchase per Title Individual articles are sold on the displayed price.

Acta Microbiologica et Immunologica Hungarica
Language English
Size A4
Year of
Foundation
1954
Publication
Programme
2021 Volume 68
Volumes
per Year
1
Issues
per Year
4
Founder Magyar Tudományos Akadémia
Founder's
Address
H-1051 Budapest, Hungary, Széchenyi István tér 9.
Publisher Akadémiai Kiadó
Publisher's
Address
H-1117 Budapest, Hungary 1516 Budapest, PO Box 245.
Responsible
Publisher
Chief Executive Officer, Akadémiai Kiadó
ISSN 1217-8950 (Print)
ISSN 1588-2640 (Online)

Monthly Content Usage

Abstract Views Full Text Views PDF Downloads
Apr 2021 0 0 0
May 2021 0 0 0
Jun 2021 0 0 0
Jul 2021 0 0 0
Aug 2021 0 0 0
Sep 2021 36 3 5
Oct 2021 0 0 0